ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0313

The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis
Abstract Number: 1948

The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease
Abstract Number: 2357

The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Abstract Number: 0932

The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing
Abstract Number: 1046

The Level of RF or Anti-CCP Antibody Affect Ultrasound Synovial Findings in Patients with Rheumatoid Arthritis?
Abstract Number: 2280

The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Abstract Number: 0478

The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children
Abstract Number: 2540

The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response
Abstract Number: 0922

The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles
Abstract Number: 1118

The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project
Abstract Number: 1253

The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease
Abstract Number: 0945

The Nuclear Receptor TR4 Orchestrates Cytoskeletal Organization in a Gα12/ROCK-dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis
Abstract Number: 0473

The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing
Abstract Number: 1741

The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis
Abstract Number: 0766

The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].